Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Mangili, Alexandra ^a   Falutz, Julian ^b   Mamputu, Jean Claude ^c   Stepanians, Miganush ^d   Hayward, Brooke ^a  

^a EMD SERONO INC   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d PROMETRIKA LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TESAMORELIN; TRIACYLGLYCEROL; GROWTH HORMONE RELEASING FACTOR;

ADULT; ARTICLE; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FRAMINGHAM RISK SCORE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTION; TREATMENT DURATION; TREATMENT RESPONSE; ABDOMINAL FAT; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; ETHNOLOGY; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ABDOMINAL FAT; ADOLESCENT; ADULT; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84949024189     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140358     Document Type: Article

References (66)

1. Brown TT, Glesby MJ. Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol. 2012; 8: 11-21.
2. Cofrancesco J Jr, Freedland E, McComsey G. Treatment options for HIV-associated central fat accumulation. AIDS Patient Care STDS. 2009; 23: 5-18. doi: 10.1089/apc.2008.0067 PMID: 19055407
3. Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: The price of success. JAMA. 2006; 296: 844-854. PMID: 16905789
4. Stanley TL, Grinspoon SK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis. 2012; 205 (Suppl 3): S383-S390. doi: 10.1093/infdis/jis205 PMID: 22577212
5. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS. 2001; 15: 2441-2444. PMID: 11740195
6. Blashill AJ, Gordon JR, Safren SA. Appearance concerns and psychological distress among HIVinfected individuals with injection drug use histories: Prospective analyses. AIDS Patient Care STDS. 2012; 26: 557-561. doi: 10.1089/apc.2012.0122 PMID: 22792882
7. Duracinsky M, Lalanne C, Le Coeur S, Herrman S, Berzins B, Armstrong AR, et al. Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument-specific to HIV disease. J Acquir Immune Defic Syndr. 2012; 59: 506-515. doi: 10.1097/QAI.0b013e31824be3f2 PMID: 22293550
8. Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2010; 54: 197-203. doi: 10.1097/QAI.0b013e3181ca48bf PMID: 20035231
9. Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: The utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007; 45: 334-341. PMID: 17514019
10. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, et al. Factors associated with nonadherence to long-term highly active antiretroviral therapy: A 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother. 2009; 64: 599-606. doi: 10.1093/jac/dkp232 PMID: 19602563
11. Barbaro G, Barbarini G. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk. Chemotherapy. 2006; 52: 161-165. PMID: 16675900
12. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005; 165: 1179-1184. PMID: 15911733
13. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005; 352: 48-62. PMID: 15635112
14. Hadigan C, Meigs JB, Corcoran C, Rietschell P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001; 32: 130-139. PMID: 11118392
15. Triant VA. HIV infection and coronary heart disease: An intersection of epidemics. J Infect Dis. 2012; 205(Suppl 3):S355-S361. doi: 10.1093/infdis/jis195 PMID: 22577208
16. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, et al. Risk factors for myocardial infarction in women and men: Insights from the INTERHEART study. Eur Heart J. 2008; 29: 932-940. doi: 10.1093/eurheartj/ehn018 PMID: 18334475
17. Ghandehari H, Le V, Kamal-Bahl S, Bassin SL, Wong ND. Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int J Obes (Lond). 2009; 33: 239-248.
18. Hu G, Tuomilehto J, Silventoinen K, Sarti C, Männistö S, Jousilahti P, et al. Body mass index, waist circumference, and waist-hip ratio on the risk of total and type-specific stroke. Arch Intern Med. 2007; 167: 1420-1427. PMID: 17620537
19. Nanchahal K, Morris JN, Sullivan LM, Wilson PW. Coronary heart disease risk in men and the epidemic of overweight and obesity. Int J Obes (Lond). 2005; 29: 317-323.
20. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008; 359: 2105-2120. doi: 10.1056/NEJMoa0801891 PMID: 19005195
21. Reis JP, Macera CA, Araneta MR, Lindsay SP, Marshall SJ, Wingard DL, et al. Comparison of overall obesity and body fat distribution in predicting risk of mortality. Obesity (Silver Spring). 2009; 17: 1232-1239.
22. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004; 364: 937-952. PMID: 15364185
23. Katzmarzyk PT, Mire E, Bouchard C. Abdominal obesity and mortality: The Pennington Center Longitudinal Study. Nutr Diabetes. 2012; 2: E42. doi: 10.1038/nutd.2012.15 PMID: 23168527
24. Currier J, Scherzer R, Bacchetti P, Heymsfield S, Lee D, Sidney S, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr. 2008; 48: 35-43. doi: 10.1097/QAI.0b013e318164227f PMID: 18197118
25. Lake JE, Wohl D, Scherzer R, Grunfeld C, Sidney S, Currier JS. Regional fat deposition and cardiovascular risk in HIV infection: The FRAM study. AIDS Care. 2011; 23: 929-938. doi: 10.1080/09540121. 2010.543885 PMID: 21767228
26. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr. 2008; 48: 44-52. doi: 10.1097/QAI.0b013e31816d9ba1 PMID: 18360291
27. Scherzer R, Heymsfield SB, Lee D, Powderly G, Tien PC, Bacchetti P, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS. 2011; 25: 1405-1414. doi: 10.1097/QAD.0b013e32834884e6 PMID: 21572308
28. Guaraldi G, Zona S, Orlando G, Carli F, Ligabue G, Fiocchi F, et al. Progression of coronary artery calcium in men affected by human immunodeficiency virus infection. Int J Cardiovasc Imaging. 2012; 28: 935-941. doi: 10.1007/s10554-011-9898-y PMID: 21643942
29. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010; 24: 243-253. doi: 10.1097/QAD.0b013e328333ea9e PMID: 19996940
30. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Mamputu JC, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled Phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010; 95: 4291-4304. doi: 10. 1210/jc.2010-0490 PMID: 20554713
31. Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinsponn SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: Relationship with visceral adipose reduction. AIDS. 2011; 25: 1281-1288. doi: 10.1097/QAD.0b013e328347f3f1 PMID: 21516030
32. Stanley TL, Falutz J, Marsolais C, Morin, Soulban G, Mamputu JC, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012; 54: 1642-1651. doi: 10.1093/cid/cis251 PMID: 22495074
33. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006; 23: 469-480. PMID: 16681555
34. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735-2752. PMID: 16157765
35. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel B. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837-1847. PMID: 9603539
36. Despres JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: Implications for the prevention of cardiovascular disease. Nutr Res Rev. 1993; 6: 137-159. doi: 10. 1079/NRR19930010 PMID: 19094306
37. Hunter GR, Snyder SW, Kekes-Szabo T, Nicholson C, Berland L. Intra-abdominal adipose tissue values associated with risk of possessing elevated blood lipids and blood pressure. Obes Res. 1994; 2: 563-568. PMID: 16355516
38. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Després JP. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr. 1996; 64: 685-693. PMID: 8901786
39. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormonereleasing factor in patients with HIV. N Engl J Med. 2007; 357: 2359-2370. PMID: 18057338
40. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008; 22: 1719-1728. doi: 10.1097/QAD.0b013e32830a5058 PMID: 18690162
41. Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010; 53: 311-322. doi: 10.1097/QAI.0b013e3181cbdaff PMID: 20101189
42. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004; 53: 2087-2094. PMID: 15277390
43. Falutz J. Management of fat accumulation in patients with HIV infection. Curr HIV/AIDS Rep. 2011; 8: 200-208. doi: 10.1007/s11904-011-0087-3 PMID: 21739217
44. Janiszewski PM, Ross R, Despres JP, Lemieux I, Orlando G, Carli F, et al. Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: A cross-sectional study. PLoS One 2011: 6: E25032. doi: 10.1371/journal.pone.0025032 PMID: 21966404
45. González-Sales M, Barrière O, Trembaly PO, Nekka F, Mamputu JC, Boudreau S, et al. (2014) Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet 2014 Oct31 doi: 10.1007/s40262-014-0202-x
46. Stanforth PR, Jackson AS, Green JS, Gagnon J, Rankinen T, Desprès JP, et al. Generalized abdominal visceral fat prediction models for black and white adults aged 17-65 y: The HERITAGE Family Study. Int J Obes Relat Metab Disord. 2004; 28: 925-932. PMID: 15148505
47. Ellis KJ, Grund B, Visnegarwala F, Thackeray L, Miller CG, Chesson CE, et al. Visceral and subcutaneous adiposity measurements in adults: Influence of measurement site. Obesity (Silver Spring). 2007; 15: 1441-1447.
48. Greenfield JR, Samaras K, Chisholm DJ, Campbell LV. Regional intra-subject variability in abdominal adiposity limits usefulness of computed tomography. Obes Res. 2002; 10: 260-265. PMID: 11943834
49. Shen W, Punyanitya M, Wang Z, Gallagher D, St Onge MP, Albu J, et al. Visceral adipose tissue: Relations between single-slice areas and total volume. Am J Clin Nutr. 2004; 80: 271-278. PMID: 15277145
50. Shah K, Hilton TN, Myers L, Pinto JF, Luque AE, Hall WJ. A new frailty syndrome: Central obesity and frailty in older adults with the human immunodeficiency virus. J Am Geriatr Soc. 2012; 60: 545-549. doi: 10.1111/j.1532-5415.2011.03819.x PMID: 22315957
51. Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB. Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr. 2013; 63: 209-215. doi: 10.1097/QAI.0b013e318289bb7e PMID: 23392468
52. Leng SX, Cappo a AR, Andersen RE, Blackman MR, Koenig K, Blair M, et al. Serum levels of insulinlike growth-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res. 2004; 16: 153-157. PMID: 15195991
53. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002; 50: 889-896. PMID: 12028177
54. Jankowski CM, Gozansky WS, Van Pelt RE, Schenkman ML, Wolfe P, Schwartz RS, et al. Relative contributions of adiposity and muscularity to physical function in community-dwelling older adults. Obesity (Silver Spring). 2008; 16: 1039-1044.
55. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007; 116: 39-48. PMID: 17576866
56. Smith JD, Borel AL, Nazare JA, Haffner SM, Balkau B, Ross R. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: Results from the INSPIRE ME IAA study. J Clin Endocrinol Metab. 2012; 97: 1517-1525. doi: 10.1210/jc.2011-2550 PMID: 22337910
57. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: An epidemiological perspective. Eur J Pharmacol. 2008; 585: 119-129. doi: 10.1016/j.ejphar.2008.02.048 PMID: 18384771
58. Thomas GN, Ho SY, Lam KS, Janus ED, Hedley AJ, Lam TH. Impact of obesity and body fat distribution on cardiovascular risk factors in Hong Kong Chinese. Obes Res. 2004; 12: 1805-1813. PMID: 15601976
59. Marques MD, Santos RD, Parga JR, Rocha-Filho JA, Quaglia LA, Miname MH, et al. Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. Atherosclerosis. 2010; 209: 481-486. doi: 10.1016/j.atherosclerosis.2009.10.023 PMID: 19922936
60. Lo J, Abbara S, Rocha-Filho JA, Shturman L, Wei J, Grinspoon SK. Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. AIDS. 2010; 24: 2127-2130. doi: 10.1097/QAD.0b013e32833c055a PMID: 20588167
61. Guaraldi G, Scaglioni R, Zona S, Orlando G, Carli F, Ligabue G, et al. Epicardial adipose tissue is an independent marker of cardiovascular risk in HIV-infected patients. AIDS. 2011; 25: 1199-1205. doi: 10.1097/QAD.0b013e3283474b9f PMID: 21505301
62. Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: A prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol. 2013; 47: 182-187. doi: 10.1097/MCG.0b013e318264181d PMID: 23059409
63. Orlando G, Guaraldi G, Zona S, Carli F, Bagni P, Menozzi M, et al. Ectopic fat is linked to prior cardiovascular events in men with HIV. J Acquir Immune Defic Syndr. 2012; 59: 494-497. doi: 10.1097/QAI. 0b013e31824c8397 PMID: 22410868
64. Freitas P, Carvalho D, Santos AC, Madureira AJ, Martinez E, Pereira J, et al. Carotid intima media thickness is associated with body fat abnormalities in HIV-infected patients. BMC Infect Dis. 2014; 2014 Jun 23; 14:348. doi: 10.1186/1471-2334-14-348 PMID: 24958511
65. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA. 2014; 312: 380-389. doi: 10.1001/jama.2014.8334 PMID: 25038357
66. Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizayaka Y, Oka R, Okada M, et al. Reduction of Visceral Fat Correlates with the Decrease in the Number of Obesity-Related Cardiovascular Risk Factors in Japanese with Abdominal Obesity (VACATION-J Study). J Atheroscler Thromb. 2012; 19: 1006-1018. PMID: 22785136